**Supplementary Materials**

Table-S1: Severity categories used when categorising laboratory abnormalities occurring after dupilumab initiation

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Type of abnormality** | **Normal range in adults** | **Mild** | **Moderate** | **Severe** | **Reference / Source** |
| Anaemia | 130-180g/L (M)  120-170g/L (F) | 110-129 g/L (M)  110-119 g/L (F) | 80-109 g/L (M&F) | <80 g/L (M&F) | [1](https://www.who.int/vmnis/indicators/haemoglobin.pdf) |
| Eosinophilia | 0-0.4x109/L | 0.5-1.5 x109/L | 1.5-5 x109/L | >5 x109/L | [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188379/#:~:text=The%20degree%20of%20eosinophilia%20associated,to%20eosinophil%20levels%20above%201500.) |
| Lympho-paenia | 1-4x109/L | >0.5 x109/L | <0.5 x109/L |  | 3 |
| Neutrophilia | 1.8-7.5x109/L | 7.5-20 x109/L | 20-50 x109/L | >50 x109/L | Author consensus |
| Thrombo-cytopaenia | 150-450 x109/L | 100-149 | 50-99 | 0-49 | 4 |
| Raised total cholesterol | <5mmol/L | 5-6.2mmol/L | >6.2mmol/L |  | 5 |
| Reduced eGFR | >90ml/min/1.73m2 | 60-90 | 45-59 | 15-44 | 6 |
| Raised bilirubin | 0-20µmol/L | <1.5x upper limit of normal | >1.5x upper limit |  | 7 and author consensus |
| Raised ALT | 7-40U/L | <2x upper limit of normal | >2x upper limit |  | 7 and author consensus |
| Raised ALP | 30-130U/L | <2x upper limit of normal | >2x upper limit |  | 7 and author consensus |
| Raised GGT | <73U/L | <2x upper limit of normal | >2x upper limit |  | Author consensus |

The following abnormalities were not categorised by severity: microcytosis, lipid profile abnormalities, positive connective tissue disease screen, raised C-reactive protein, raised total immunoglobulin E.

ALP = alkaline phosphatase. ALT = alanine aminotransferase. eGFR = estimated glomerular filtration rate. F = female. g = grams. GGT = gamma-glutamyl transferase. L = litre. M = male. U = units.

References:

1. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. WHO/NMH/NHD/MNM/11.1. <http://www.who.int/vmnis/indicators/haemoglobin.pdf> (accessed 29/10/2020).
2. Rosenwasser LJ. Approach to patients with eosinophilia. Mo Med. 2011;108(5):358-60.
3. Chung K-P, Chang H-T, Lo S-C, Chang L-Y, Lin S-Y, Cheng A, et al. Severe Lymphopenia Is Associated with Elevated Plasma Interleukin-15 Levels and Increased Mortality During Severe Sepsis. Shock. 2015;43(6):569-75.
4. Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest. 2013;144(4):1207-15.
5. Mayo Foundation for Medical Education and Research. Cholesterol test. <https://www.mayoclinic.org/tests-procedures/cholesterol-test/about/pac-20384601> (accessed 29/10/2020).
6. The Renal Association. The UK eCKD Guide, 2017. <https://renal.org/health-professionals/information-resources/uk-eckd-guide> (accessed 29/10/2020).
7. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT02776033, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis; 2016 May 18 [cited 2020 Oct 29]; [Available from: http://clinicaltrials.gov/ct/show/NCT02776033].